AUA: Genomic Urine Test Accurately Predicts Bladder Cancer
MONDAY, May 15, 2023– A new genomic urine test can predict bladder cancer as many as 12 years before clinical signs and symptoms emerge, according to a study presented at the annual meeting of the American Urological Association, held from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 15, 2023 Category: Pharmaceuticals Source Type: news
Novel Chemo Delivery System Achieves High Response Rate in Bladder Cancer
(MedPage Today) -- CHICAGO -- An investigational intravesical delivery system designed to provide sustained local release of gemcitabine into the bladder produced high rates of complete response (CR) in difficult-to-treat non-muscle-invasive... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 2, 2023 Category: Hematology Source Type: news
'Fantastic,' 'Terrific' Results With Oncolytic Virus Combo for Bladder Cancer
(MedPage Today) -- CHICAGO -- An oncolytic virus therapy combined with pembrolizumab (Keytruda) produced complete responses (CRs) in 85% of patients with bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 2, 2023 Category: Hematology Source Type: news
Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Gu érin-Unresponsive Non-Muscle-Invasive Bladder Cancer
CHICAGO, April 30, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first results from the open-label Phase 2 SunRISe-1 study evaluating the efficacy and safety of TAR-200 monotherapy (a novel investigational intravesical drug delivery system) and cetrelimab monotherapy (an investigational anti-PD-1 monoclonal antibody administered intravenously) in patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC), who are ineligible for, or decline, radical cystectomy. The study demonstrated that 72.7 percent of patients treated wit...
Source: Johnson and Johnson - April 30, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
S2 Episode 2: How Bladder Cancer Immunostimulant N-803 May Shake Things Up S2 Episode 2: How Bladder Cancer Immunostimulant N-803 May Shake Things Up
Drs Cheryl Lee and Karim Chamie talk about efforts to develop nogapendekin alfa, aka N-803, and where it may fit into the shifting treatment paradigm for non –muscle-invasive bladder cancer.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 20, 2023 Category: Consumer Health News Tags: Urology InDiscussion Source Type: news
S2 Episode 1: Breaking Bladder Cancer Barriers: Promise of Gene Therapy S2 Episode 1: Breaking Bladder Cancer Barriers: Promise of Gene Therapy
Drs Cheryl Lee and Stephen Boorjian share detailed insights about a model drug development partnership involving the first-in-class therapy for BCG-unresponsive non –muscle-invasive bladder cancer.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 20, 2023 Category: Consumer Health News Tags: Urology InDiscussion Source Type: news
Johnson & Johnson Reports Q1 2023 Results
New Brunswick, N.J. (April 18, 2023) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2023. “Our first quarter results demonstrate strong performance across all three segments of our business and reflect the dedication of Johnson & Johnson colleagues around the world,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “With this momentum, I look forward to the remainder of the year, one filled with exciting catalysts that will create both near- and long-term value for patients and all of our stakeholders.”OVERALL FINANCIAL RESULTSQ1($ in Millions, except EPS)2...
Source: Johnson and Johnson - April 18, 2023 Category: Pharmaceuticals Tags: Financial Source Type: news
Bladder Cancer in Women: What to Know
One in every 91 women will develop bladder cancer in her lifetime, according to data from the American Cancer Society. And Chinese research finds that women with the disease have a worse prognosis than men. Here's what to know. (Source: WebMD Health)
Source: WebMD Health - April 14, 2023 Category: Consumer Health News Source Type: news
FDA Greenlights New First-Line Regimen in Bladder Cancer
(MedPage Today) -- The FDA gave accelerated approval to enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) as first-line treatment for certain patients with locally advanced or metastatic urothelial cancer, the agency announced on Monday... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 4, 2023 Category: Hematology Source Type: news
Haematuria is the 'most common' sign of bladder cancer seen in 85% of patients
Paying attention to any changes in your urine could mean the difference between spotting potential cancerous changes and letting them slip under the radar. (Source: Daily Express - Health)
Source: Daily Express - Health - April 3, 2023 Category: Consumer Health News Source Type: news
What are Presentations of Neuroblastoma?
Discussion
Abdominal pain is a very common problem with abdominal masses being somewhat less common. If one considers how frequently patients have abdominal pain due to constipation and that it often presents with a fecal mass, both of these are commonplace. Abdominal and pelvic organs are sometimes mistaken for masses also. As the abdominal and pelvic cavities are large, tumors often need to be quite large before they cause functional problems and/or can be palpated on physical examination.
A review of abdominal masses can be found here.
A review of recurrent abdominal pain can be found here.
A review of acute abdominal p...
Source: PediatricEducation.org - March 27, 2023 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
A Pentagon Study Finds Higher Cancer Rates in Military Pilots and Ground Crews
WASHINGTON — A Pentagon study has found high rates of cancer among military pilots and for the first time has shown that ground crews who fuel, maintain and launch those aircraft are also getting sick.
The data had long been sought by retired military aviators who have raised alarms for years about the number of air and ground crew members they knew who had cancer. They were told that earlier military studies had found they were not at greater risk than the general U.S. population.
In its yearlong study of almost 900,000 service members who flew on or worked on military aircraft between 1992 and 2017, the Pentagon fo...
Source: TIME: Health - March 20, 2023 Category: Consumer Health News Authors: Tara Copp/AP Tags: Uncategorized Cancer healthscienceclimate wire Source Type: news
Trial Casts Shadow on Photodynamic Surgery for Bladder Cancer Trial Casts Shadow on Photodynamic Surgery for Bladder Cancer
Photodynamic diagnosis-guided TURBT did not reduce 3-year recurrence rates of non –muscle-invasive bladder cancer in a real-world trial compared with white light-guided cystoscopy.Medscape Medical News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - March 15, 2023 Category: Pathology Tags: Hematology-Oncology News Source Type: news
Urine Test Predicts Future Bladder Cancer 12 Years Before Symptoms Urine Test Predicts Future Bladder Cancer 12 Years Before Symptoms
A 10-gene assay predicted future cases of urothelial cancer, the most common form of bladder cancer, with a high degree of sensitivity and specificity.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 13, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Gemcitabine, Docetaxel a Viable Alternative to BCG in Bladder Cancer
MONDAY, March 13, 2023 -- For patients with non-muscle invasive bladder cancer (NMIBC), gemcitabine and docetaxel therapy is associated with less high-grade disease recurrence, according to a study published online Feb. 28 in JAMA Network Open.
Ian... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 13, 2023 Category: Pharmaceuticals Source Type: news
